BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29954690)

  • 1. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.
    Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Soulières D; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2018 Oct; 16(5):376-384.e1. PubMed ID: 29954690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
    Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
    Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
    Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
    Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    Ali A; Hoyle A; Mistry H; Clarke NW
    BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients.
    Budnik J; Suri J; Bates JE; Bylund KC; Milano MT
    Clin Genitourin Cancer; 2019 Aug; 17(4):260-267. PubMed ID: 31101579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
    Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
    Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
    Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
    Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites.
    Tappero S; Piccinelli ML; Incesu RB; Cano Garcia C; Barletta F; Morra S; Scheipner L; Baudo A; Tian Z; Parodi S; Dell'Oglio P; de Cobelli O; Graefen M; Chun FKH; Briganti A; Longo N; Ahyai S; Carmignani L; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Apr; 22(2):47-55.e2. PubMed ID: 37690970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other-cause mortality in incidental prostate cancer.
    Di Bello F; Baudo A; de Angelis M; Jannello LMI; Siech C; Tian Z; Goyal JA; Collà Ruvolo C; Califano G; La Rocca R; Morra S; Acquati P; Saad F; Shariat SF; Carmignani L; de Cobelli O; Briganti A; Chun FKH; Longo N; Karakiewicz PI
    Prostate; 2024 Jun; 84(8):731-737. PubMed ID: 38506561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
    Pascale M; Azinwi CN; Marongiu B; Pesce G; Stoffel F; Roggero E
    BMC Cancer; 2017 Sep; 17(1):651. PubMed ID: 28923109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
    Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
    Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
    Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
    Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
    He H; Han D; Xu F; Lyu J
    Prostate; 2022 Mar; 82(4):415-424. PubMed ID: 34927741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of developing visceral metastases at diagnosis in prostate cancer patients.
    Xu N; Wu YP; Ke ZB; Liang YC; Tao X; Chen SH; Li XD; Cai H; Lin YZ; Lin TT; Xue XY
    Transl Cancer Res; 2019 Jun; 8(3):928-938. PubMed ID: 35116832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
    Shou J; Zhang Q; Wang S; Zhang D
    Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
    Bandini M; Pompe RS; Marchioni M; Zaffuto E; Gandaglia G; Fossati N; Cindolo L; Montorsi F; Briganti A; Saad F; Karakiewicz PI
    Int Urol Nephrol; 2018 Jan; 50(1):71-78. PubMed ID: 29129028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.